Discover why long-term investment-grade bonds like IGLB excel when rates fall. Explore their yields and performance.
RBI Grade B Phase 1 Exam 2025 was held on 18th and 19th October. Candidates can now gear up for the next stage: Phase 2.
Despite a rate cut, Treasury yields climbed — highlighting market uncertainty and shifting expectations for future policy.
USA TODAY College Sports Wire on MSN
Iowa Football: Report card tumultuous from Hawkeyes' win over Penn State
Let's start with the bad. Iowa gave some room to Penn State RB Kayton Allen, who got loose for 145 and two touchdowns against ...
MedPage Today on MSN
Who Knew? Autoimmunity Might Actually Benefit Some Cancer Patients
Some 68% of patients with autoimmune disease had "major" side effects from CAR-T therapy for myeloma, lymphoma, or leukemia, ...
“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...
Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...
MedPage Today on MSN
First Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast Cancer
BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall ...
The Federal Reserve’s September interest rate cut has triggered a shift in the corporate bond market, with spreads in both ...
New KEYNOTE-B96 data add to previous results showing progression-free survival (PFS) and overall survival (OS) improvements ...
Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...
The Food and Drug Administration (FDA) has approved Gazyva ® (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results